Skip to main content

Table 1 Baseline characteristics of patients on somatostatin analogue treatment for metastatic disease from small-intestinal neuroendocrine tumour

From: Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours

 Baseline N = 881-year follow-up N = 77
Males,n(%)47 (53.4%) 
Age, median (range)65.0 (32–87) years 
Time since diagnosis, median (range)4.82 (0.3–34.3) years 
Time since first treatment, median (range)3.09 (0.2–15.3) years 
Weight, median (range)72.5 (40–130) kg70.0 (40–132) kg
Weight change from baseline, median (range) 0.0 (−15–13) kg
Weight loss in the last year,n(%)
None61 (69.3%)51 (67.1%)b
0–5%18 (20.5%)17 (22.4%)b
6–10%7 (8.0%)6 (7.9%)b
> 10%2 (2.3%)2 (2.6%)b
Occupation,n(%)
Retired53 (60.2%)50 (66.7%)b
Non-retired35 (39.8%)25 (33.3%)b
Working (% of non-retired)15 (42.9%)12 (48.0%)b
Not working (% of non-retired)20 (57.1%)13 (52.0%)b
Disease status,n(%)
Metastatic mesenteric lymph nodes34 (38.6%) 
Other metastatic lymph nodes35 (39.8%) 
Liver metastases78 (88.8%) 
Lung metastases1 (1.1%) 
Other metastases23 (26.1%) 
Surgery of primary tumour,n(%)74 (84.1%) 
Surgery of mesenteric lymph nodes42 (49.4%)b 
Surgery of liver metastases14 (17.1%)b 
Ki67, median (min-max)1.0% (1–15%) 
Ki67, categorised
0–2%60 (68.2%) 
> 2%28 (31.8%) 
Performance status,n(%)
049 (55.7%)48 (62.3%)
131 (35.2%)16 (20.8%)
27 (8.0%)11 (14.3%)
31 (1.1%)2 (2.6%)
Smoker,n(%)11 (12.6%)b 
Prior treatments
Interferon22 (25.0%)4 (5.2%)c
PRRT21 (23.9%)19 (24.7%)c
5-HIAA in urine, above normal,n(%)42 (79.2%)b25 (83.3%)b
CgA in blood, above normal,n(%)64 (72.7%)55 (75.3%)b
Pancreatic enzyme supplement,n(%)
Current use26 (29.5%)27 (35.5%)b
Prior and current use39 (44.3%)NA
Loperamide,n(%)
Current use20 (22.7%)17 (22.4%)b
Prior and current use38 (43.2%)NA
Cholestyramine,n(%)
Current use6 (6.8%)6 (7.9%)b
Prior and current use13 (14.8%)NA
Vitamin supplements,n(%)
Current use59 (67.0%)64 (83.1%)
  1. 5-HIAA 5-hydroxyindoleacetic acid, CgA Chromogranin A, ECOG Eastern Cooperative Oncology Group, PRRT peptide receptor radionuclide therapy